MMPAD Milan Meeting Report

7 European Roadshow - Milan, 29 June 2018 MEETING REPORT may be nonspecific, directed against T and B cells, cytokines or co-stimulatory molecules (they act as anti-CD3, abatacept and teplizumab, against CTLA4-Ig still abatacept, and as anti-CD20 rituximab), or antigen-specific (ASI), based on the administration of autoantigens (insulin, GAD65, MonoPepT1De, MultiPepT1De). There are also many combination therapy options, including anti-inflammatory agents (such as anti-IFN and anti-TNF), immunomodulators, autoantigens and beta-cell preservers (such as GLP1-receptor agonists). The real problem is to adequately characterise the children to be treated. Future perspectives focus on characterising young patients and the design of "tailor-made" studies that could perhaps succeed in prevention, where previous approaches have failed.